What were the top posts here on The Niche for the past year? I’ve listed some of them below along with some posts from 2015 that remain highly read. Some top 2016 posts 20 Nominees for Stem Cell Person of the […]
The 21st Century Cures Act has some important provisions that would impact the stem cell and regenerative medicine field. What is driving these efforts is a widespread sense that the status quo of regenerative medicine oversight isn’t working very well. […]
Will Trump trump the FDA? Our President-elect recently released his health care policy agenda and it looks like the FDA is a target in terms of reducing oversight. Over at the Washington Post, Carolyn Johnson has a nice article on this development. […]
One of the biggest stem cell news stories of 2016 has been the REGROW Act, a bill intended to accelerate investigational stem cell and regenerative medicine therapies to patients by lessening FDA oversight, but in the last couple months REGROW […]
Today was the first part of the FDA’s 2-day meeting on stem cell draft guidances. It was a great meeting I thought. A few consistent themes and notable things emerged as raised by participants.